Cargando…
Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1α
Dysregulation of miRNAs has been shown to contribute to multiple tumorigenic processes, as well as to correlate with tumour progression and prognosis. miR-199a has been shown to be dysregulated in multiple tumour types. However, the association between miR-199a and the chemoresistance features of os...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859113/ https://www.ncbi.nlm.nih.gov/pubmed/28442599 http://dx.doi.org/10.1042/BSR20170080 |
_version_ | 1783471075683729408 |
---|---|
author | Keremu, Ajimu Aini, Abudureyimu Maimaitirexiati, Yusufuaji Liang, Zhilin Aila, Pazila Xierela, Paizila Tusun, Aikebaier Moming, Hanikezi Yusufu, Aihemaitijiang |
author_facet | Keremu, Ajimu Aini, Abudureyimu Maimaitirexiati, Yusufuaji Liang, Zhilin Aila, Pazila Xierela, Paizila Tusun, Aikebaier Moming, Hanikezi Yusufu, Aihemaitijiang |
author_sort | Keremu, Ajimu |
collection | PubMed |
description | Dysregulation of miRNAs has been shown to contribute to multiple tumorigenic processes, as well as to correlate with tumour progression and prognosis. miR-199a has been shown to be dysregulated in multiple tumour types. However, the association between miR-199a and the chemoresistance features of osteosarcoma are not well understood, the target genes for miR-199a and the regulatory mechanisms are also unknown. In the present study, we demonstrated that miR-199a is expressed at low levels in osteosarcoma cells and patient samples. By the selection and establishment of cisplatin resistant osteosarcoma cell line, we observed a correlation between miR-199a and cisplatin resistance in osteosarcoma cells: resistant cells exhibit attenuated miR-199a expressions and exogenous overexpression of miR-199a sensitizes osteosarcoma cells to cisplatin. Moreover, we identified HIF-1α as a direct target for miR-199a. Intriguingly, cisplatin resistant osteosarcoma cells display significantly elevated HIF-1α expression under hypoxia. We report here overexpression of miR-199a resensitizes cisplatin resistant cells to cisplatin through inhibition of HIF-1α in vitro and in vivo. Finally, by analysing the clinical osteosarcoma patient samples, we demonstrate a reverse correlation between miR-199a and HIF-1α mRNAs. Our study will provide mechanisms for the miRNA-mediated anticancer therapy and miR-199a may be considered a promising therapeutic agent for osteosarcoma patients who fail to respond to conventional chemotherapy. |
format | Online Article Text |
id | pubmed-6859113 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-68591132019-11-29 Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1α Keremu, Ajimu Aini, Abudureyimu Maimaitirexiati, Yusufuaji Liang, Zhilin Aila, Pazila Xierela, Paizila Tusun, Aikebaier Moming, Hanikezi Yusufu, Aihemaitijiang Biosci Rep Cancer Dysregulation of miRNAs has been shown to contribute to multiple tumorigenic processes, as well as to correlate with tumour progression and prognosis. miR-199a has been shown to be dysregulated in multiple tumour types. However, the association between miR-199a and the chemoresistance features of osteosarcoma are not well understood, the target genes for miR-199a and the regulatory mechanisms are also unknown. In the present study, we demonstrated that miR-199a is expressed at low levels in osteosarcoma cells and patient samples. By the selection and establishment of cisplatin resistant osteosarcoma cell line, we observed a correlation between miR-199a and cisplatin resistance in osteosarcoma cells: resistant cells exhibit attenuated miR-199a expressions and exogenous overexpression of miR-199a sensitizes osteosarcoma cells to cisplatin. Moreover, we identified HIF-1α as a direct target for miR-199a. Intriguingly, cisplatin resistant osteosarcoma cells display significantly elevated HIF-1α expression under hypoxia. We report here overexpression of miR-199a resensitizes cisplatin resistant cells to cisplatin through inhibition of HIF-1α in vitro and in vivo. Finally, by analysing the clinical osteosarcoma patient samples, we demonstrate a reverse correlation between miR-199a and HIF-1α mRNAs. Our study will provide mechanisms for the miRNA-mediated anticancer therapy and miR-199a may be considered a promising therapeutic agent for osteosarcoma patients who fail to respond to conventional chemotherapy. Portland Press Ltd. 2019-11-15 /pmc/articles/PMC6859113/ /pubmed/28442599 http://dx.doi.org/10.1042/BSR20170080 Text en © 2019 The Author(s). https://creativecommons.org/licenses/by/4.0/ This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). |
spellingShingle | Cancer Keremu, Ajimu Aini, Abudureyimu Maimaitirexiati, Yusufuaji Liang, Zhilin Aila, Pazila Xierela, Paizila Tusun, Aikebaier Moming, Hanikezi Yusufu, Aihemaitijiang Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1α |
title | Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1α |
title_full | Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1α |
title_fullStr | Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1α |
title_full_unstemmed | Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1α |
title_short | Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1α |
title_sort | overcoming cisplatin resistance in osteosarcoma through the mir-199a-modulated inhibition of hif-1α |
topic | Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859113/ https://www.ncbi.nlm.nih.gov/pubmed/28442599 http://dx.doi.org/10.1042/BSR20170080 |
work_keys_str_mv | AT keremuajimu overcomingcisplatinresistanceinosteosarcomathroughthemir199amodulatedinhibitionofhif1a AT ainiabudureyimu overcomingcisplatinresistanceinosteosarcomathroughthemir199amodulatedinhibitionofhif1a AT maimaitirexiatiyusufuaji overcomingcisplatinresistanceinosteosarcomathroughthemir199amodulatedinhibitionofhif1a AT liangzhilin overcomingcisplatinresistanceinosteosarcomathroughthemir199amodulatedinhibitionofhif1a AT ailapazila overcomingcisplatinresistanceinosteosarcomathroughthemir199amodulatedinhibitionofhif1a AT xierelapaizila overcomingcisplatinresistanceinosteosarcomathroughthemir199amodulatedinhibitionofhif1a AT tusunaikebaier overcomingcisplatinresistanceinosteosarcomathroughthemir199amodulatedinhibitionofhif1a AT mominghanikezi overcomingcisplatinresistanceinosteosarcomathroughthemir199amodulatedinhibitionofhif1a AT yusufuaihemaitijiang overcomingcisplatinresistanceinosteosarcomathroughthemir199amodulatedinhibitionofhif1a |